Low serum IGF-I/GH ratio is associated with abnormal glucose tolerance in acromegaly
- PMID: 18219220
- DOI: 10.1159/000112590
Low serum IGF-I/GH ratio is associated with abnormal glucose tolerance in acromegaly
Abstract
Background/aims: Acromegaly is frequently accompanied with impaired glucose tolerance (IGT) and diabetes mellitus (DM). It remains unclear which factors determine the abnormal glucose tolerance status in acromegaly. In addition, diverse actions of GH and IGF-I in regulating glucose metabolism in acromegaly have not yet been well elucidated. The aim of this study was to investigate the factors associated with abnormal glucose tolerance in acromegaly.
Subjects and study design: We conducted a retrospective cross-sectional study that included 48 patients with active acromegaly. The subjects were divided into two groups by the results of 75 g OGTT: normal glucose tolerance (NGT) group (n = 19) and IGT+DM group (n = 29).
Results: Systolic blood pressure (SBP) was significantly higher in the IGT+DM than in the NGT group. Homeostasis model assessment of beta-cell function (HOMA-beta) was significantly decreased in the IGT+DM group compared with the NGT group. Although serum GH or IGF-I levels were not different between the two groups, the IGF-I/GH ratio in the IGT+DM group was significantly lower than that in the NGT group.
Conclusions: We have shown that a low serum IGF-I/GH ratio was associated with abnormal glucose tolerance in acromegaly. We propose that the IGF-I/GH ratio is a useful marker to understand the metabolic status in acromegaly.
(c) 2008 S. Karger AG, Basel
Similar articles
-
Clinical indicators of biochemical remission in acromegaly: does incomplete disease control always mean therapeutic failure?Clin Endocrinol (Oxf). 2005 Apr;62(4):410-7. doi: 10.1111/j.1365-2265.2005.02233.x. Clin Endocrinol (Oxf). 2005. PMID: 15807870
-
[Application of hyperglycemic clamp technique in the assessment of beta-cell function in obese individuals with glucose intolerance].Zhonghua Yi Xue Za Zhi. 2004 Nov 2;84(21):1781-4. Zhonghua Yi Xue Za Zhi. 2004. PMID: 15631773 Chinese.
-
Metabolic characteristics of subjects with normal glucose tolerance and 1-h hyperglycaemia.Clin Endocrinol (Oxf). 2008 Oct;69(4):575-9. doi: 10.1111/j.1365-2265.2008.03209.x. Epub 2008 Jan 31. Clin Endocrinol (Oxf). 2008. PMID: 18248638
-
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.Acta Diabetol. 2009 Jun;46(2):85-95. doi: 10.1007/s00592-009-0112-9. Epub 2009 Mar 26. Acta Diabetol. 2009. PMID: 19322513 Review.
-
[Discrepancy between IGF-1 and GH during 75 g oral glucose tolerance test measures to acromegaly screening in a patient with macroprolactinoma--case report and literature review].Arq Bras Endocrinol Metabol. 2007 Apr;51(3):494-9. doi: 10.1590/s0004-27302007000300020. Arq Bras Endocrinol Metabol. 2007. PMID: 17546251 Review. Portuguese.
Cited by
-
Preoperative octreotide therapy and surgery in acromegaly: associations between glucose homeostasis and treatment response.Endocrine. 2016 Feb;51(2):298-307. doi: 10.1007/s12020-015-0679-6. Epub 2015 Jul 16. Endocrine. 2016. PMID: 26179177 Clinical Trial.
-
Secondary diabetes mellitus in acromegaly.Endocrine. 2023 Jul;81(1):1-15. doi: 10.1007/s12020-023-03339-1. Epub 2023 Mar 8. Endocrine. 2023. PMID: 36882643 Free PMC article. Review.
-
HOMA-IR in acromegaly: a systematic review and meta-analysis.Pituitary. 2021 Apr;24(2):146-158. doi: 10.1007/s11102-020-01092-6. Epub 2020 Oct 21. Pituitary. 2021. PMID: 33085039
-
Insulin-like growth factor I, growth hormone, and insulin sensitivity: the effects of a one-year cholecalciferol supplementation in middle-aged overweight and obese subjects.Endocrine. 2013 Apr;43(2):412-8. doi: 10.1007/s12020-012-9825-6. Epub 2012 Oct 30. Endocrine. 2013. PMID: 23109222 Clinical Trial.
-
Preoperative Fasting C-Peptide Acts as a Promising Predictor of Improved Glucose Tolerance in Patients With Acromegaly After Transsphenoidal Surgery: A Retrospective Study of 64 Cases From a Large Pituitary Center in China.Front Endocrinol (Lausanne). 2019 Nov 1;10:736. doi: 10.3389/fendo.2019.00736. eCollection 2019. Front Endocrinol (Lausanne). 2019. PMID: 31736874 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources